DelveInsight’s, “Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Relapsed Refractory Acute Myeloid Leukemia R R Emerging drugs, the Relapsed Refractory Acute Myeloid Leukemia R R pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Relapsed Refractory Acute Myeloid Leukemia R R pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Relapsed Refractory Acute Myeloid Leukemia R R clinical trials studies, Relapsed Refractory Acute Myeloid Leukemia R R NDA approvals (if any), and product development activities comprising the technology, Relapsed Refractory Acute Myeloid Leukemia R R collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Report

 

• DelveInsight’s relapsed/refractory acute myeloid leukemia pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for relapsed/refractory acute myeloid leukemia treatment.

 

• The leading Relapsed Refractory Acute Myeloid Leukemia R R Companies include Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.

 

• Promising Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Therapies include MAX-40279-01, UCART123v1.2, AMG 427, AMG 553, APG-2575, XY0206, Fosciclopirox, AB8939, MRX2843, CD123 CAR-T cells, ASP7517, Ceraxa, CLN-049,  Crenolanib, Uproleselan, KITE-222, CYAD-02, VOB560, TAA05, MK-0482, ASTX660, 6MW3211, SNDX-5613, MRX-2843, CB-5339, CG-806, NEI-01, RC1012, RO7283420, IO-202, PRT1419, LAVA-051, PRGN-3006 T Cells, CYNK-001, SKLB1028, CWP232291, E7820, WU-NK-101, DSP-533, ADCT-301,I MGN632, APVO436,  FHD-286, TCB008,  SH1573, NKX101 – CAR NK cell therapy, LP-108,  and others.

 

• The Relapsed/refractory Acute Myeloid Leukemia Companies and academics are working to assess challenges and seek opportunities that could influence Relapsed/refractory acute myeloid leukemia (AML) R&D. The Relapsed/refractory Acute Myeloid Leukemia pipeline therapies under development are focused on novel approaches to treat/improve Relapsed/refractory acute myeloid leukemia (AML).

 

Request a sample and discover the recent breakthroughs happening in the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline landscape @ Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Outlook Report

 

Relapsed Refractory Acute Myeloid Leukemia R R Overview

Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. The prognosis of relapsed acute myeloid leukemia (AML) is poor and treatment is challenging. The signs and symptoms of acute myeloid leukemia (AML) are common to other, less serious illnesses.

 

Recent Developmental Activities in the Relapsed/Refractory Acute Myeloid Leukemia Treatment Landscape

 

• In August 2022, Foghorn® Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) had placed a full clinical hold on the Phase 1 dose escalation study of FHD-286, an inhibitor of BRG1/BRM, in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The dose escalation Phase 1 study of FHD-286 in metastatic uveal melanoma (mUM) continues per protocol. The company plans to report data from the mUM study in the first half of 2023.

 

• In May 2022, Aptose Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. Currently, an international Phase 1/2 clinical trial is ongoing for HM43239 in the R/R AML patient population. HM43239 received orphan drug designation from the FDA for the treatment of acute myeloid leukemia in 2018.

 

• In April 2022, Precigen, Inc. announced that the FDA had granted Fast Track designation for PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) AML. PRGN-3006 was previously granted FDA Orphan Drug Designation.

 

• In March 2022, Aptevo Therapeutics, a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced that a patient with relapsed/refractory acute myeloid leukemia or AML in a monotherapy arm of its on-going Phase 1b trial evaluating adult patients with AML, had received an allogeneic stem cell transplant subsequent to receiving APVO436 and experiencing a significant reduction in bone marrow blasts. This follows the Company’s previous announcement that a patient receiving combination therapy is also moving to transplant after one cycle of therapy.

 

• In December 2021, Notable Labs, Inc. initiated a Phase 1B/2A clinical trial of fosciclopirox in patients with refractory acute myelogenous leukemia (AML) under the terms of a co-development agreement.

 

• In December 2021, Astellas Pharma Inc. announced the presentation of new investigational data in acute myeloid leukemia (AML) and sickle cell disease at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition (December 11-14) in Atlanta, Ga. 

 

• In December 2021, Syndax Pharmaceuticals, Inc. announced updated positive data from the Phase 1 dose escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias. SNDX-5613 is the Company’s highly selective oral menin inhibitor. 

 

• In June 2021, Cullinan Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared Cullinan Florentine’s IND application for CLN-049, a FLT3 x CD3 bispecific antibody for the treatment of relapsed/refractory acute myeloid leukemia (AML).

 

For further information, refer to the detailed Relapsed Refractory Acute Myeloid Leukemia R R Drugs Launch, Relapsed Refractory Acute Myeloid Leukemia R R Developmental Activities, and Relapsed Refractory Acute Myeloid Leukemia R R News, click here for Relapsed Refractory Acute Myeloid Leukemia R R Ongoing Clinical Trial Analysis

 

Relapsed/refractory acute myeloid leukemia (AML) Emerging Drugs

 

• APG-2575: Ascentage Pharma

APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).

 

• CLN 049: Cullinan Oncology

CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.

 

• Lanraplenib:  Kronos Bio

Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.

 

Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Relapsed/refractory acute myeloid leukemia (AML). The companies which have their Relapsed/refractory acute myeloid leukemia (AML) drug candidates in the most advanced stage, i.e. Phase I/II include, Ascentage Pharma.

 

Find out more about the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Segmentation, Therapeutics Assessment, and Relapsed Refractory Acute Myeloid Leukemia R R Emerging Drugs @ Relapsed Refractory Acute Myeloid Leukemia R R Treatment Landscape

 

Scope of the Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Report

 

• Coverage- Global

 

• Relapsed Refractory Acute Myeloid Leukemia Companies- Maxinovel Pty., Ltd., Cellectis S.A., Amgen, Ascentage Pharma, Shijiazhuang Yiling Pharmaceutical, CicloMed LLC, AB Science, Betta Pharmaceuticals Co., Ltd., Chongqing Precision Biotech Co., Ltd, Astellas Pharma, Keystone Nano, Cullinan Oncology, LLC, Arog Pharmaceuticals, Inc., GlycoMimetics Incorporated, Kite Pharma, Celyad Oncology SA, Novartis, PersonGen Biotherapeutics, Merck Sharp & Dohme LLC, Astex Pharmaceuticals, Mabwell (Shanghai) Bioscience Co., Ltd., Syndax Pharmaceuticals, Meryx, Inc., Cleave Therapeutics, Aptose Biosciences Inc., New Epsilon Innovation Limited, Guangdong Ruishun Biotech Co., Ltd, Hoffmann-La Roche, Prelude Therapeutics, Lava Therapeutics, Precigen, Inc, Celularity Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., JW Pharmaceutical, Eisai Inc., Wugen, Inc., Sumitomo Pharma Oncology, Inc., ADC Therapeutics S.A., ImmunoGen, Inc., Aptevo Therapeutics, Foghorn Therapeutics, TC Biopharm, Nanjing Sanhome Pharmaceutical, Co., Ltd., Nkarta Inc., Newave Pharmaceutical Inc,, and others.

 

• Relapsed Refractory Acute Myeloid Leukemia Pipeline Therapies- MAX-40279-01, UCART123v1.2, AMG 427, AMG 553, APG-2575, XY0206, Fosciclopirox, AB8939, MRX2843, CD123 CAR-T cells, ASP7517, Ceraxa, CLN-049,  Crenolanib, Uproleselan, KITE-222, CYAD-02, VOB560, TAA05, MK-0482, ASTX660, 6MW3211, SNDX-5613, MRX-2843, CB-5339, CG-806, NEI-01, RC1012, RO7283420, IO-202, PRT1419, LAVA-051, PRGN-3006 T Cells, CYNK-001, SKLB1028, CWP232291, E7820, WU-NK-101, DSP-533, ADCT-301,I MGN632, APVO436,  FHD-286, TCB008,  SH1573, NKX101 – CAR NK cell therapy, LP-108,  and others.

 

• Relapsed Refractory Acute Myeloid Leukemia Segmentation: Product Type, Mechanism of Action, Route of Administration, Molecule Type 

 

Dive deep into rich insights for drugs for Relapsed Refractory Acute Myeloid Leukemia R R Pipeline Companies and Therapies, click here @ Relapsed Refractory Acute Myeloid Leukemia R R Unmet Needs and Analyst Views

 

Introduction

1. Relapsed/refractory acute myeloid leukemia Executive Summary
2. Relapsed/refractory acute myeloid leukemia (AML): Overview
3. Relapsed/refractory acute myeloid leukemia Pipeline Therapeutics
4. Relapsed/refractory acute myeloid leukemia Therapeutic Assessment
5. Relapsed/refractory acute myeloid leukemia (AML)– DelveInsight’s Analytical Perspective
6. Late Stage Products (Phase III)
7. Drug name : Company name
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase I/II)
10. APG-2575: Ascentage Pharma
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. CLN 049: Cullinan Oncology
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name : Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
20. Relapsed/refractory acute myeloid leukemia (AML) Key Products
21. Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
22. Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
23. Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
24. Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
25. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
26. Appendix

 

Got Queries? Find out the related information on Relapsed Refractory Acute Myeloid Leukemia R R Mergers and acquisitions, Relapsed Refractory Acute Myeloid Leukemia R R Licensing Activities @ Relapsed Refractory Acute Myeloid Leukemia R R Emerging Drugs, and Recent Trends

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/